In vitro susceptibility testing of Helicobacter pylori to antimicrobial agents: basis for treatment or microbiologists' obsession? (Q40800925)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8280946%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

review article

1 reference

title

In vitro susceptibility testing of Helicobacter pylori to antimicrobial agents: basis for treatment or microbiologists' obsession? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8280946%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

0 references

Y Glupczynski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8280946%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

publication date

1 September 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8280946%20AND%20SRC:MED&resulttype=core&format=json

Zentralblatt fur Bakteriologie : international journal of medical microbiology

28 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8280946%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

volume

280

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8280946%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

issue

1-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8280946%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

page(s)

227-238

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8280946%20AND%20SRC:MED&resulttype=core&format=json

The efficacy of antimicrobial treatment in Campylobacter pylori-associated gastritis and duodenal ulcer.

28 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Cure of duodenal ulcer after eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Cure of duodenal ulcer associated with eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Treatment failure of ofloxacin in Campylobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Treatment failure of norfloxacin against Campylobacter pylori and chronic gastritis in patients with nonulcerative dyspepsia

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Role of metronidazole resistance in therapy of Helicobacter pylori infections

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Susceptibility of clinical isolates of campylobacter pylori to 24 antimicrobial and anti-ulcer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones.

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

In vitro activity of antifungal azoles against Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Activity of the antimycotic ketoconazole against Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Evaluation of a new selective medium for Campylobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Bactericidal effect of amoxicillin on Helicobacter pylori in an in vitro model using epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Bactericidal activity of antimicrobial agents against slowly growing Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

In vitro selection of resistant Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Drug resistance of Helicobacter pylori: memorandum from a meeting at the Sixth International Workshop on Campylobacter, Helicobacter, and Related Organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro--an ultrastructural study

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Proposed mechanism for metronidazole resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Metronidazole-resistant Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

The minimum inhibitory concentrations of various bismuth salts against Campylobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori)

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Sensitivity of Campylobacter pylori to colloidal bismuth subcitrate

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Antibacterial activity of pantoprazole and omeprazole againstHelicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

In vitro activity of metronidazole against Helicobacter pylori as determined by agar dilution and agar diffusion

1 reference

https://api.crossref.org/works/10.1016%2FS0934-8840%2811%2980960-6

7 January 2021

10.1016/S0934-8840(11)80960-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8280946%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8280946%20AND%20SRC:MED&resulttype=core&format=json